Molteno Implant With Mitomycin C

Perkins, Todd W.; Gangnon, Ronald E.; Ladd, William M.; Kaufman, Paul L.; Libby, Curtis M.

doi:10.1097/00061198-199804000-00004

Cited by 32 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alvarado et al [86] found that the use of high concentrations and application time of MMC also offer better hypotensive effect. On the other several other authors have reported that the intraoperative use of MMC did not improve the results of the GDD implantation [87][88][89][90].…”

Section: Antimetabolites and Anti-vegfmentioning

confidence: 89%

Combined Cataract-Glaucoma Surgery

Kozobolis¹,

Konstantinidis²,

Labiris³

2013

Glaucoma - Basic and Clinical Aspects

View full text Add to dashboard Cite

Section: Antimetabolites and Anti-vegfmentioning

confidence: 89%

Combined Cataract-Glaucoma Surgery

Kozobolis¹,

Konstantinidis²,

Labiris³

2013

Glaucoma - Basic and Clinical Aspects

View full text Add to dashboard Cite

“…24 There have been contradictory reports about the effect of antifibrotic agents on glaucoma implant surgeries. [25][26][27][28][29][30] In this study, when the subjects were divided into two groups, the mitomycin C treated group and the untreated group, there was no difference not only in preoperative variables such as age, sex, preoperative intraocular pressure, and number of preoperative antiglaucoma medications but also in the intraocular pressure at the last visit. The success rate was higher in the mitomycin C group, but it was not significant statistically.…”

Section: -6 23mentioning

confidence: 92%

Clinical experience of e-PTFE membrane implant surgery for refractory glaucoma

Kim

Kim²,

Choi³

et al. 2003

British Journal of Ophthalmology

View full text Add to dashboard Cite

Aims: To evaluate the clinical efficacy of membrane tube implant made of expanded polytetrafluoroethylene (e-PTFE, Gore-Tex) membrane and silicone tube in treating refractory glaucoma. Methods: A retrospective chart review was performed on 43 eyes of 40 patients who underwent glaucoma tube shunt implant surgery using double layered e-PTFE membrane and silicone tube to treat refractory glaucoma. The surgeries were performed from May 1991 to September 1995, and the subjects were patients with terminal glaucoma without useful vision on the study eye. Results: The mean follow up period was 32.9 months. The Kaplan-Meier survival for intraocular pressure (IOP) control (IOP between 6 and 21mm Hg without significant complication) was 80.9% at 1 year, 73.9% at 2 years, and 62.2% at 3 years after surgery. After excluding three eyes of three patients who were dropped within 3 months after surgery and did not have any serious complication or problem in IOP control, the average preoperative IOP was 42.5 (SD 14.6) mm Hg and IOP on the last visit was 17.3 (10.2) mm Hg (p = 0.000, n = 40). The number of antiglaucoma medications before surgery (2.2 (0.6)) was reduced to 0.5 (0.8) on the last visit (p = 0.000). The IOP was controlled within the range of 6-21 mm Hg in 26 eyes (65.0%). In the remaining 14 eyes (35%), we could not control the IOP or additional surgery was needed to control the IOP or to treat severe complications. Two cases of endophthalmitis and three of phthisis were found as serious complications. The other complications were similar to those of other commercially available glaucoma implants. Conclusion: A comparable clinical result was obtained with this new implant as with the other commercially available implants. This implant with a thin and non-rigid reservoir has a potential to reduce some complications associated with the large volume and rigid consistency of the other implants, although it is not yet proved. This membrane tube implant may be considered as another substitute in the surgery of refractory glaucoma.

show abstract

“…Despite reports of their efficacy in successfully controlling bleb scarring, 70,71 the American Academy of Ophthalmology 33 and randomized clinical trials 72,73 have concluded that the use of antifibrotic agents presents no additional benefits in glaucoma filtering procedures. Few new potential antimetabolites, such as ilomastat, bevacizumab, and rapamycin, are currently investigated.…”

Section: Filtering and End-stage Glaucoma Proceduresmentioning

confidence: 99%